Predicting biopsy-proven prostate cancer recurrence following cryosurgery

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 4, 2012, Pages 391-395

  Caso, Jorge R ^a   Tsivian, Matvey ^a   Mouraviev, Vladimir ^a   Polascik, Thomas J ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cryosurgery; Prostate cancer; Prostate specific antigen; Recurrence

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CORRELATION ANALYSIS; CRYOSURGERY; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PREDICTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RECURRENCE RISK; RISK ASSESSMENT; RISK REDUCTION;

5-ALPHA REDUCTASE INHIBITORS; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY; COMBINED MODALITY THERAPY; CRYOSURGERY; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 84862985084     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.04.001     Document Type: Article

References (18)

1. Polascik T.J., Nosnik I., Mayes J.M., et al. Short-term cancer control after primary cryosurgical ablation for clinically localized prostate cancer using third-generation cryotechnology. Urology 2007, 70:117-121.
2. Zisman A., Pantuck A.J., Cohen J.K., et al. Prostate cryoablation using direct transperineal placement of ultrathin probes through a 17-gauge brachytherapy template-technique and preliminary results. Urology 2001, 58:988-993.
3. Babaian R.J., Donnelly B., Bahn D., et al. Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol 2008, 180:1993-2004.
4. Bahn D.K., Lee F., Badalament R., et al. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology 2002, 60:3-11.
5. Cohen J.K., Miller R.J., Ahmed S., et al. Ten-year biochemical disease control for patients with prostate cancer treated with cryosurgery as primary therapy. Urology 2008, 71:515-518.
6. Jones J.S., Rewcastle J.C., Donnelly B.J., et al. Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry. J Urol 2008, 180:554-558.
7. Levy D.A., Pisters L.L., Jones J.S. Primary cryoablation nadir prostate specific antigen and biochemical failure. J Urol 2009, 182:931-937.
8. Spiess P.E., Lee A.K., Leibovici D., et al. Pre-salvage prostate-specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy. Cancer 2006, 107:275-280.
9. Daskivich T.J., Regan M.M., Oh W.K. Prostate specific antigen doubling time calculation: Not as easy as 1, 2, 4. J Urol 2006, 176:1927-1937.
10. Donnelly B.J., Saliken J.C., Ernst D.S., et al. Prospective trial of cryosurgical ablation of the prostate: five-year results. Urology 2002, 60:645-649.
11. Ellis D.S. Cryosurgery as primary treatment for localized prostate cancer: a community hospital experience. Urology 2002, 60:34-39.
12. Cresswell J., Asterling S., Chaudhary M., et al. Third-generation cryotherapy for prostate cancer in the UK: A prospective study of the early outcomes in primary and recurrent disease. BJU Int 2006, 97:969-974.
13. Long J.P., Bahn D., Lee F., et al. Five-year retrospective, multi-institutional pooled analysis of cancer-related outcomes after cryosurgical ablation of the prostate. Urology 2001, 57:518-523.
14. Consensus statement: Guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997, 37:1035-1041.
15. Roach M., Hanks G., Thames H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006, 65:965-974.
16. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280:969-974.
17. Valicenti R.K., DeSilvio M., Hanks G.E., et al. Post-treatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: An analysis of Radiation Therapy Oncology Group Protocol 92-02. Int J Radiat Oncol Biol Phys 2006, 66:1064-1071.
18. Chang S.L., Freedland S.J., Terris M.K., et al. Freedom from a detectable ultrasensitive prostate-specific antigen at 2 years after radical prostatectomy predicts a favorable clinical outcome: Analysis of the SEARCH database. Urology 2010, 75:439-444.